Next Article in Journal
Multifunctional Cement Composites Strain and Damage Sensors Applied on Reinforced Concrete (RC) Structural Elements
Next Article in Special Issue
The Development of Novel Near-Infrared (NIR) Tetraarylazadipyrromethene Fluorescent Dyes
Previous Article in Journal
Characterization and Stability of Tanshinone IIA Solid Dispersions with Hydroxyapatite
Previous Article in Special Issue
Solubilization of Hydrophobic Dyes in Surfactant Solutions
Open AccessReview

Dye Sensitizers for Photodynamic Therapy

Fiber and Polymer Science Program, North Carolina State University, Raleigh, NC 27695-8301, USA
Author to whom correspondence should be addressed.
Materials 2013, 6(3), 817-840;
Received: 31 January 2013 / Revised: 20 February 2013 / Accepted: 22 February 2013 / Published: 6 March 2013
(This article belongs to the Special Issue Advances in Colorants)
Photofrin® was first approved in the 1990s as a sensitizer for use in treating cancer via photodynamic therapy (PDT). Since then a wide variety of dye sensitizers have been developed and a few have been approved for PDT treatment of skin and organ cancers and skin diseases such as acne vulgaris. Porphyrinoid derivatives and precursors have been the most successful in producing requisite singlet oxygen, with Photofrin® still remaining the most efficient sensitizer (quantum yield = 0.89) and having broad food and drug administration (FDA) approval for treatment of multiple cancer types. Other porphyrinoid compounds that have received approval from US FDA and regulatory authorities in other countries include benzoporphyrin derivative monoacid ring A (BPD-MA), meta-tetra(hydroxyphenyl)chlorin (m-THPC), N-aspartyl chlorin e6 (NPe6), and precursors to endogenous protoporphyrin IX (PpIX): 1,5-aminolevulinic acid (ALA), methyl aminolevulinate (MAL), hexaminolevulinate (HAL). Although no non-porphyrin sensitizer has been approved for PDT applications, a small number of anthraquinone, phenothiazine, xanthene, cyanine, and curcuminoid sensitizers are under consideration and some are being evaluated in clinical trials. This review focuses on the nature of PDT, dye sensitizers that have been approved for use in PDT, and compounds that have entered or completed clinical trials as PDT sensitizers. View Full-Text
Keywords: photodynamic therapy; photosensitizers; porphyrins; clinical trials; target organs photodynamic therapy; photosensitizers; porphyrins; clinical trials; target organs
Show Figures

Figure 1

MDPI and ACS Style

Ormond, A.B.; Freeman, H.S. Dye Sensitizers for Photodynamic Therapy. Materials 2013, 6, 817-840.

AMA Style

Ormond AB, Freeman HS. Dye Sensitizers for Photodynamic Therapy. Materials. 2013; 6(3):817-840.

Chicago/Turabian Style

Ormond, Alexandra B.; Freeman, Harold S. 2013. "Dye Sensitizers for Photodynamic Therapy" Materials 6, no. 3: 817-840.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop